Ribbon Acquisition Corp
RIBB
NASDAQ Global Select10.80
USD
+0.04
- -
Ribbon Acquisition Corp
RIBB
(NASDAQ Global Select)
Recent
price
10.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ribbon Acquisition Corp. (NASDAQ: RIBB) operates as a blank check company whose principal business activity is to pursue a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. Incorporated in 2024 and headquartered at Central Park Tower, LaTour Shinjuku Room 3001, 6-15-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan, the company currently conducts no significant operations and focuses exclusively on identifying and completing an initial business combination opportunity. It offers no products or services beyond its SPAC structure, including Class A ordinary shares, units and rights traded on the Nasdaq Global Market under the symbols RIBB, RIBBU and RIBBR respectively; fiscal year ends December 31 with reporting in U.S. dollars. In June 2025, Ribbon Acquisition entered into a definitive business combination agreement with DRC Medicine Ltd., a Tokyo-based healthcare and biotechnology firm developing advanced medical technologies such as Hydro Silver Titanium devices, therapeutic masks for allergic rhinitis and in vitro diagnostic kits; the transaction implies a pre-money equity value of $350 million for DRC on a fully diluted basis and approximately $422.15 million pro forma for the combined entity, with DRC shareholders retaining 100% of their equity and expected to own 82.91% post-combination. The deal, subject to shareholder approval and regulatory clearances, anticipates providing up to $50.42 million in gross proceeds from Ribbon's trust account (assuming no redemptions) to fund DRC's clinical trials, R&D commercialization and operations, with a Registration Statement on Form S-4 to be filed including a proxy statement/prospectus. Ribbon completed its initial public offering in January 2025, raising $50 million through 5 million units priced at $10 each (upsized to $52.2 million), led by CEO and Chairman Angshuman Ghosh and CFO Zhiyang Zhou. The company targets sectors including healthcare without specified geographic limitations beyond its Japanese base.